LSPN 19: Two bites at the apple here to stay, says Alkermes director
Petitioners will continue to be able to launch litigation simultaneously before both the district court and the Patent Trial and Appeal Board (PTAB), effectively having two bites at the apple, according to John Kirkland, director of IP at biopharmaceutical company Alkermes.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
21 April 2022 Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
21 April 2022 Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.
21 April 2022 Irish biopharmaceutical company Alkermes has entered arbitration proceedings over two license agreements with Johnson & Johnson subsidiary Janssen Pharmaceuticals.